(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10446 A2

(51) International Patent Classification[7]: A61K 31/565, 31/66, 9/08, 47/42, A61P 35/00

(21) International Application Number: PCT/EP00/07678

(22) International Filing Date: 3 August 2000 (03.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9918779.1 9 August 1999 (09.08.1999) GB
MI99A001998 27 September 1999 (27.09.1999) IT

(71) Applicant *(for all designated States except US)*: PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MUGGETTI, Lorena [IT/IT]; Via Trento, 38, I-20036 Meda (IT). COLOMBO, Paolo [IT/IT]; Via Ludovico Cavaleri, 3, I-20147 Milan (IT). MARTINI, Alessandro [IT/IT]; Via Desidcrio da Settignano, 14, I-20149 Milano (IT). BUZZI, Giovanni [IT/IT]; Via F. Poggi, 14, I-20131 Milan (IT).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/10446 A2

(54) Title: FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND ALBUMIN

(57) Abstract: A pharmaceutical formulation which comprises a parenterally acceptable carrier or a diluent and estramustine phosphate in admixture with human albumin, wherein the weight ratio of estramustine phosphate to human albumin is from about 1:5 to about 1:0.3. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustine phosphate to be administered with no side effects at the side of injection.